Keyarch Acquisition Corp. announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “KYCHU” Tuesday, January 25.
The new SPAC intends to focus its search for a target on disruptive technology and innovative services companies in developed economies such as the U.S. and Israel, and Southeast Asia. Keyarch is led by Chairman Fang Zhang, CEO Kai Xiong, and CFO Jing Lu.
Total SPAC deal count for 2022 year-to-date is now 22. This offering is expected to close on Thursday, January 27.
EarlyBirdCapital,Inc. and Haitong International Securities are acting as the joint book-running managers for the offering with Revere Securities as co-manager. Orrick, Herrington & Sutcliffe LLP is serving as Issuer’s Counsel with Graubard Miller serving as Underwriter’s Counsel. UHY LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Terms Tracker for the Week Ending May 3, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. The big news this week was that SPACs finally had a new IPO price with Churchill Capital Corp. IX’s $250 million offering on Thursday. SPACs...
Real estate marketplace Opendoor (NASDAQ:OPEN) is poised to be the latest de-SPAC to take a double-digit jump on earnings as it heads towards the weekend up +10%, having spiked as high as +27% earlier in the day. The movement comes as the former Social Capital II target reported progress towards profitability despite a high rates...
At the SPAC of Dawn Coinbase (NASDAQ:COIN) notched a surprise profit of over $1.5 billion in the first quarter of 2024, well exceeding estimates, demonstrating the powerful effect of publicly traded ETFs have had on crypto marketplaces since the start of the year. The result has pushed the company to bump up its own guidance...
Online casino and sports company Rush Street (NYSE:RSI) is up +18.4% in trading today on the back of a solid first quarter earnings release, bringing the company’s stock to its highest price since the second half of 2022 (currently $7.60). This makes it the latest in a line of 2020 and 2021 de-SPACs that have...
Mountain Crest V (NASDAQ:MCAG) broke a long dealmaking silence by SPACs this morning, albeit with a non-binding agreement to combine with Seoul-based diagnostic biotech firm CUBEBIO. The term sheet would give the company a $620 million pre-transaction equity value and help accelerate the rollout of CUBEBIO’s CEED-NOVUS cancer screening kit products. The company signed an...